[Role of neoadjuvant chemotherapy in the advanced ovarian cancer].
Primary surgery is still thought as cornerstone in treating locally advanced epithelial ovarian cancer. Subsequent to surgery is usually chemotherapy. Survival of patients with advanced epithelial ovarian cancer, according to International Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV, who make over 75% of total patients with ovarian cancer is still unsatisfactory. With these patients it is often impossible to perform adequate resection of all changes in the abdomen (optimal debulking) and so is the effectiveness of chemotherapy decreased. Therefore as a possible optimal approach appears neoadjuvant chemotherapy (NAC) that leads to the decreasing of the primary tumour and possible metastasis in the abdomen. With such an approach an operation procedure is shorter and easier after 3-4 cycles of chemotherapy with a stronger possibility of optimal "debulking".